Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Investigating the effect of dolutegravir-based antiretroviral therapy during pregnancy on placental characteristics and function

FY 2025-26

Summary
Every year, 1.3 million people living with HIV (PLHIV) become pregnant, and about 85% receive antiretroviral therapy (ART) during pregnancy, drastically reducing rates of perinatal transmission. However, safety data for the use of ART during pregnancy lags far behind that for nonpregnant PLHIV. Further, pregnant PLHIV experience worse pregnancy outcomes, including stillbirth, preterm delivery, low birth weight and mortality compared to pregnant people who are HIV-negative. The reasons behind this disparity remain unknown. In the new era of long-acting ARTs, and as more PLHIV conceive while on ART, there is a renewed call for action to accelerate the inclusion of pregnant people in HIV treatment and prevention research. This project directly responds to this call for safety data by investigating dolutegravir (DTG), a drug used by millions of people of reproductive age globally. DTG is a first-line ART recommended by the World Health Organization, American, and Canadian treatment guidelines for all PLHIV, including during pregnancy. Concerningly, studies have reported an association between DTG and a higher incidence of hypertensive disorders in pregnancy (HDP) (e.g., gestational hypertension and preeclampsia), which, in addition to haemorrhage, are the leading causes of maternal deaths globally. Thus, this project aims to inform the ongoing search for an optimal ART regimen for pregnant PLHIV by linking understandings of DTG and HDPs, an issue with global implications for research, policy, and practice.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572632
Name
Gibson Kyla L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the effect of dolutegravir-based antiretroviral therapy during pregnancy on placental characteristics and function
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Antiretroviral Therapy; Dolutegravir; Hiv; Hypertensive Disorders Of Pregnancy; Placenta
Abstract
Every year, 1.3 million people living with HIV (PLHIV) become pregnant, and about 85% receive antiretroviral therapy (ART) during pregnancy, drastically reducing rates of perinatal transmission. However, safety data for the use of ART during pregnancy lags far behind that for nonpregnant PLHIV. Further, pregnant PLHIV experience worse pregnancy outcomes, including stillbirth, preterm delivery, low birth weight and mortality compared to pregnant people who are HIV-negative. The reasons behind this disparity remain unknown. In the new era of long-acting ARTs, and as more PLHIV conceive while on ART, there is a renewed call for action to accelerate the inclusion of pregnant people in HIV treatment and prevention research. This project directly responds to this call for safety data by investigating dolutegravir (DTG), a drug used by millions of people of reproductive age globally. DTG is a first-line ART recommended by the World Health Organization, American, and Canadian treatment guidelines for all PLHIV, including during pregnancy. Concerningly, studies have reported an association between DTG and a higher incidence of hypertensive disorders in pregnancy (HDP) (e.g., gestational hypertension and preeclampsia), which, in addition to haemorrhage, are the leading causes of maternal deaths globally. Thus, this project aims to inform the ongoing search for an optimal ART regimen for pregnant PLHIV by linking understandings of DTG and HDPs, an issue with global implications for research, policy, and practice.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gibson, Kyla L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~